09.30.14
L'Oréal has been granted a Chinese business licence for Shanghai Episkin Biotechnology Ltd., which will market its reconstructed skin models, Episkin. These models are essential for the validation of alternative methods to animal testing for cosmetic products and ingredients.
This alternative method will make it possible to evaluate the safety of products and ingredients without animal testing.
Laurent Attal, Executive Vice-President of Research and Innovation at L'Oréal, explains:
"Over the past 30 years, our researchers have developed the expertise of reconstructing skin and other human tissues. An investment in science and a strong ethical commitment have led us to implement several alternative methods and embrace the era of predictive assessment. Worldwide, we share our methods and tools and offer training to universities and authorities. With this objective in mind, we started producing reconstructed Asian skin in China in 2008, so that in the near future we can begin marketing it through Shanghai Episkin Biotechnology."
This alternative method will make it possible to evaluate the safety of products and ingredients without animal testing.
Laurent Attal, Executive Vice-President of Research and Innovation at L'Oréal, explains:
"Over the past 30 years, our researchers have developed the expertise of reconstructing skin and other human tissues. An investment in science and a strong ethical commitment have led us to implement several alternative methods and embrace the era of predictive assessment. Worldwide, we share our methods and tools and offer training to universities and authorities. With this objective in mind, we started producing reconstructed Asian skin in China in 2008, so that in the near future we can begin marketing it through Shanghai Episkin Biotechnology."